HitGen Inc. (SHA:688222)
China flag China · Delayed Price · Currency is CNY
23.90
+0.46 (1.96%)
Last updated: Aug 1, 2025

HitGen Company Description

HitGen Inc. operates as a drug discovery research platform for small molecules and nucleic acid drugs in China and internationally.

Its technology platform includes DNA-encoded library technology; fragment-based drug discovery and structure-based drug design technologies; emerging technology platforms for synthetic therapeutic oligonucleotide technology; and targeted protein degradation technology.

The company’s product pipeline includes HG146, a selective HDAC inhibitor for multiple myeloma and solid tumor; HG030, a second generation NTRK/ROS1 inhibitor tablet for solid tumor; HG153 a Menin-MLL tablet; HG248; and HG 381, an immune-oncology agonist for cancer, as well as HGP0508, a small molecule for anti-inflammatory therapeutics for inflammation; HGP1069, a ROCK2 inhibitor eye drop.

Further, it offers target validation, hit identification, hit-to-lead optimization, lead optimization, preclinical studies and IND, clinical development, and integrated drug discovery services.

Additionally, the company focus on oncology and immuno-oncology, inflammatory and autoimmune diseases, ophthalmology, infectious, metabolic, and cardiovascular diseases.

HitGen Inc. was founded in 2012 and is based in Chengdu, China.

HitGen Inc.
CountryChina
Founded2012
IndustryBiotechnology
SectorHealthcare
Employees483
CEOLi Jin

Contact Details

Address:
Building C2
Chengdu, 610200
China
Phone86 28 8519 7385
Websitehitgen.com

Stock Details

Ticker Symbol688222
ExchangeShanghai Stock Exchange
Fiscal YearJanuary - December
Reporting CurrencyCNY
SIC Code8731

Key Executives

NamePosition
Li JinChairman and GM
Dr. Hongge Liu CFA, Ph.D.Chief Financial Officer
Shiwei GengSecretary
Dengfeng DouDeputy General Manager
Guansai LiuDeputy General Manager
Chunyan HuAccounting Supervisor
Barry A. MorganChief Scientist